Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Presidential Symposium I

4506 - Results of the phase III IFCT-0302 trial assessing minimal versus CT-scan-based follow-up for completely resected non-small cell lung cancer (NSCLC)


09 Sep 2017


Presidential Symposium I


Cancers in Adolescents and Young Adults (AYA);  Staging Procedures (not Imaging);  Surgical Oncology;  Radiation Oncology;  Non-Small Cell Lung Cancer


Virginie Westeel


Annals of Oncology (2017) 28 (suppl_5): v449-v452. 10.1093/annonc/mdx378


V. Westeel1, F. Barlesi2, P. Foucher3, J. Lafitte4, J. Domas5, P. Girard6, J. Tredaniel7, M. Wislez8, P. Dumont9, E. Quoix10, O. Raffy11, D. Braun12, M. Derollez13, F. Goupil14, J. Hermann15, E. Devin16, E. Pichon17, J. Gury18, F. Morin19, P. Souquet20

Author affiliations

  • 1 Pneumologie, CHRU Besançon, Hôpital Jean Minjoz, 25030 - Besançon/FR
  • 2 Multidisciplinary Oncology & Therapeutic Innovations, Aix Marseille University - Assistance Publique des Hôpitaux de Marseille, Marseille/FR
  • 3 Pneumologie, CHU Le Bocage (Dijon), 21079 - Dijon/FR
  • 4 Pneumologie, CHRU Lille - Hôpital Calmette, Lille/FR
  • 5 Pneumologie, Centre Catalan d'Oncologie Clinique St. Pierre, 66000 - Perpignan/FR
  • 6 Pneumologie, Institut Mutualiste Montsouris, Paris/FR
  • 7 Pneumologie, Hopital St. Joseph, 75014 - Paris/FR
  • 8 Pneumologie, APHP, CancerEst, Tenon University Hospital, 75020 - Paris/FR
  • 9 Pneumologie, Centre Hospitalier, 2303 - Chauny/FR
  • 10 Service De Pneumologie - Pôle De Pathologie Thoracique, NHC, CHU Strasbourg, Strasbourg/FR
  • 11 Pneumologie, Centre Hospitalier, Chartres/FR
  • 12 Pneumologie, Cabinet, Briey/FR
  • 13 Pneumologie, Clinique de Val de Sambre, Maubeuge/FR
  • 14 Pneumologie, Centre Hospitalier, Le Mans/FR
  • 15 Pneumologie, HPMetz - Hôpital Robert Schuman, Metz/FR
  • 16 Pneumologie, CHI EureSeine - Evreux, Evreux/FR
  • 17 Pneumologie, CHRU Bretonneau, 37044 - Tours/FR
  • 18 Pneumologie, Centre Hospitalier, Vesoul/FR
  • 19 Clinical Research Unit, French Cooperative Thoracic Intergroup, 75009 - Paris/FR
  • 20 Pneumologie, Centre Hospitalier Lyon Sud, 69495 - Pierre Bénite/FR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4506


Several guidelines recommend a follow-up based on clinic visits and chest CT-scans for completely resected NSCLC. However, evidence to support these recommendations is poor, in the absence of randomized data. The IFCT-0302 trial is a randomized multicenter trial which compared 2 follow-up programs for completely resected stage pI, II, IIIA and T4 (pulmonary nodules in the same lobe) N0-2 NSCLC (TNM 6th edition).


In the control arm (arm 1), follow-up consisted of clinical examination and Chest X-ray (CXR). In the experimental arm (arm 2), patients underwent clinical examination, CXR, thoraco-abdominal CT-scan (CT) plus bronchoscopy (optional for adenocarcinomas). In both arms, procedures were repeated every 6 months after randomization during the first 2 years, and yearly until 5 years. Supplementary procedures were allowed in case of symptoms. The primary endpoint was overall survival (OS).


Between January 2005 and November 2012, 1775 patients were randomized (arm 1: 888; arm 2: 887). Patient characteristics were well-balanced between the two arms: males 76.3%, median age 63 years (range: 34-88), squamous and large cell carcinomas 39.5%, stage I 68.1%, stage II 13.7%, stage III 18.3%, lobectomy or bilobectomy 86.6%, pre- and/or post-operative radiotherapy 8.7%, and pre- and/or post-operative chemotherapy 45%. Median follow-up was 8.7 yrs (95% CI: 8.5-9). OS was not significantly different between arms (HR = 0.92, 95% CI: 0.8-1.07; p = 0.27). Median OS was 8.2 yrs (95% CI: 7.4-9.6) and 10.3 yrs (95% CI: 8.5-not reached) in arms 1 and 2, respectively. Three-year disease-free survival rates were 63.3% (95%CI: 60.2%-66.5%), and 60.2% (95% CI: 57.0%-63.4%), respectively. Eight-year OS rates were 51.1% (95% CI: 47.2%-55.1%) and 55.6% (95% CI: 51.7%-59.4%) respectively.


The IFCT-0302 trial is the first randomized study of follow-up in resected NSCLC. The primary endpoint was not met. A longer follow-up is necessary not to miss a potential long-term OS benefit of CT-scan-based surveillance.

Clinical trial identification


Legal entity responsible for the study

Intergroupe Francophone de Cancérologie Thoracique (IFCT)


Ministère de la Santé (PHRC), Fondation de France, Laboratoire Lilly


E. Quoix: Non-financial support from AMGEN, Pfizer, BMS. Personal fees from Abbvie, Clovis and Lilly. Personal fees and non-financial support from Boehringer Ingelheim. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.